UNSPSC 51172323: Glucarpidase

This classification denotes an enzyme replacement preparation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2GFP9BJD79. European Medicines Agency schedules Glucarpidase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25203. Glucarpidase generally arises in the molecular formula 4ZN. The term GLUCARPIDASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations schedule glucarpidase under HS 35079090 and SITC 51691.

As of Q4 2014, GLUCARPIDASE remains the US FDA Preferred Term for this commodity. Glucarpidase bears US NLM identifiers UMLS ID C0007072 and NCI Concept Code C346. SMILES: none.

UNSPSC 51172323 Glucarpidase, a Commodity code, does not align with the state and local procurement activity indexed under it. The single recent opportunity sourced—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—concerns immunoassay screening, LC/MS/MS and GC/MS confirmation testing, oral fluid and hair testing methodologies, and lab certification compliance (SAMHSA, TX DPS, or CAP). Glucarpidase is a specific pharmaceutical agent used in oncology to treat methotrexate toxicity; it does not appear in the scope of the Collin County RFP or in typical state and local drug-testing procurement. The code shows little relevant recent activity for business development purposes.

The Collin County opportunity, posted September 25, 2026 with a response deadline of July 23, 2026, carries an estimated contract value of $600,000 over a two-year term with up to three optional one-year renewals. The county seeks staffing of two collection sites (Plano and McKinney), operation of an Interactive Voice Response system for randomized testing notifications, and handling approximately 25,031 annual tests across five-panel and six-panel screening models. Evaluation emphasizes vendor understanding and firm qualifications (55 combined points), client references (15 points), and cost (30 points), with optional Phase 2 demonstrations and interviews worth up to 30 additional points. Funding derives from Texas Department of Criminal Justice-Community Justice Assistance Division appropriations, subject to annual availability. The anticipated award date is August 10, 2026.